Cargando…
A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer
A phase 1 clinical trial was conducted to assess the safety, tolerability, and preliminary efficacy of a heterologous prime-boost strategy involving plasmid DNA (pHM-GM-CSF, expressing truncated human epidermal growth factor receptor 2 (HER2) and granulocyte macrophage colony-stimulation factor (GM-...
Autores principales: | Kim, Sung-Bae, Ahn, Jin-Hee, Kim, Jeongeun, Jung, Kyung Hae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588449/ https://www.ncbi.nlm.nih.gov/pubmed/26445724 http://dx.doi.org/10.1038/mtm.2015.31 |
Ejemplares similares
-
Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022) -
Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
por: Kim, Hyun Jung, et al.
Publicado: (2020) -
Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023) -
Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2014) -
Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu(+ )metastatic breast cancer in mice
por: Wang, Xiaoyan, et al.
Publicado: (2005)